The Pharmacokinetics of Anagrelide in Elderly and Young Patients With Essential Thrombocythaemia (ET)
Launched by SHIRE · Dec 19, 2006
Trial Information
Current as of June 05, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Young patients aged 18-50 years inclusive or Elderly patients aged 65 years and over
- • Patients must have a confirmed diagnosis of ET.
- • Currently receiving anagrelide hydrochloride at a stable maintenance dose \< 5 mg/day for at least 4 weeks.
- Exclusion Criteria:
- • Diagnosis of any other myeloproliferative disorder.
- • Current use of tobacco in any form (e.g. smoking or chewing)
- • Treatment with any known enzyme altering agents (barbiturates, phenothiazines, cimetidine etc.) within 30 days prior to or during the study.
- • Patients for whom use of another cytoreductive agent in addition to anagrelide is considered necessary for control of platelet count.
About Shire
Shire, a global biotechnology company, specializes in developing innovative therapies for rare diseases and complex conditions. With a strong commitment to improving the lives of patients, Shire focuses on areas such as hematology, immunology, neuroscience, and genetic disorders. The company is dedicated to advancing clinical research and delivering breakthrough treatments that address unmet medical needs. Through collaboration and a patient-centric approach, Shire strives to enhance health outcomes and empower individuals affected by challenging health conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Barcelona, , Spain
Lulea, , Sweden
Uppsala, , Sweden
Uppsala, , Sweden
Belfast, , United Kingdom
Patients applied
Trial Officials
Study Director
Study Director
Takeda
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials